Compare TENX & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | BARK |
|---|---|---|
| Founded | 1967 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 73.7M |
| IPO Year | 2001 | 2020 |
| Metric | TENX | BARK |
|---|---|---|
| Price | $1.48 | $9.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | $10.29 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.4M | 29.9K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $394,843,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $0.50 |
| 52 Week High | $19.40 | $11.32 |
| Indicator | TENX | BARK |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 64.62 |
| Support Level | $1.34 | $8.14 |
| Resistance Level | $2.01 | $9.98 |
| Average True Range (ATR) | 0.12 | 0.56 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 6.25 | 74.31 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
BARK Inc believe that dogs and humans are good together and it aspire to be the world's favorite dog brand. It is a team of dog-obsessed people committed to delivering personalization at scale by satisfying each dog's distinct personality, preferences, and needs with the products and services. It is an omnichannel brand that designs and develops proprietary products for dogs across two key brands: BarkBox and Super Chewer. All of its products are designed and developed in-house, and are BARK branded. Its segments are DTC, and Commerce. It generates majority of revenue from DTC. Direct to Consumer generates revenue from subscription products that feature monthly themes of premium quality BarkBox and Super Chewer toys and BARK-branded treats and chews.